Genetics Unit, Shriners Hospital for Children, and McGill University, Montréal, Quebec, Canada H3G 1A6.
J Clin Endocrinol Metab. 2012 Aug;97(8):E1550-6. doi: 10.1210/jc.2012-1827. Epub 2012 Jun 5.
Osteogenesis imperfecta (OI) type VI is a rare autosomal recessive bone fragility disorder that is caused by inactivating mutations in SERPINF1, the gene that encodes pigment-epithelium derived factor (PEDF). Determining PEDF serum levels might facilitate the diagnosis of OI type VI.
The objective of the study was to assess whether lack of circulating PEDF is a specific marker of OI type VI and to evaluate whether PEDF serum levels are influenced by other metabolic bone diseases.
Serum PEDF concentrations were measured in 12 patients with OI type VI (aged 2.7-31 yr) as well as in 96 children and adolescents with OI types I, III, and IV; in 26 young patients with hypophosphatemic rickets; and in 19 healthy controls.
Circulating PEDF was undetectable in all 12 patients with OI type VI but was measurable for the other 141 study participants. No significant differences in serum PEDF concentrations were found between the diagnostic groups other than OI type VI. Treatment with bisphosphonates (in OI types I, III, and IV) and with phosphate and calcitriol (in hypophosphatemic rickets) did not have a detectable influence on serum PEDF. In patients with OI types I, III, and IV, serum creatinine, body mass index z-score, and OI severity were significant predictors of PEDF serum levels.
Determining PEDF serum concentration helps to diagnose OI type VI but does not seem to provide information on the activity of bone turnover or mineralization.
成骨不全症(OI)VI 型是一种罕见的常染色体隐性遗传性骨脆弱疾病,由编码色素上皮衍生因子(PEDF)的 SERPINF1 基因失活突变引起。测定 PEDF 血清水平可能有助于 OI VI 型的诊断。
本研究旨在评估循环 PEDF 缺乏是否是 OI VI 型的特异性标志物,并评估 PEDF 血清水平是否受其他代谢性骨病的影响。
测定了 12 例 OI VI 型(年龄 2.7-31 岁)、96 例 OI I、III、IV 型儿童和青少年、26 例低磷血症性佝偻病和 19 例健康对照者的血清 PEDF 浓度。
12 例 OI VI 型患者的血清 PEDF 均无法检测到,而其他 141 例研究参与者的血清 PEDF 均可检测到。除 OI VI 型外,各诊断组之间的血清 PEDF 浓度无显著差异。用双膦酸盐(OI I、III、IV 型)、磷酸盐和骨化三醇(低磷血症性佝偻病)治疗对血清 PEDF 无明显影响。在 OI I、III、IV 型患者中,血清肌酐、体重指数 z 评分和 OI 严重程度是 PEDF 血清水平的显著预测因素。
测定 PEDF 血清浓度有助于诊断 OI VI 型,但似乎不能提供骨转换或矿化活性的信息。